Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Blood|September 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, et al.
Nature Communications|January 19, 2023
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosisJulien Broséus, Sébastien Hergalant, Julia Vogt, et al.
Eclinicalmedicine|January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO groupAnne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Blood Cancer Discovery|December 5, 2022
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic VulnerabilitiesElisa Ten Hacken, Tomasz Sewastianik, Shanye Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular LymphomaFranck Morschhauser, Loretta Nastoupil, Pierre Feugier, et al.
Haematologica|February 22, 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphomaAnastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, et al.
Blood|March 31, 2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysisNicolas Gower, Pierre Feugier, Jason R Westin, et al.
The Lancet. Oncology|October 16, 2009
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trialNatacha Heutte, Henning H Flechtner, Nicolas Mounier, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Blood|September 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, et al.
Nature Communications|January 19, 2023
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosisJulien Broséus, Sébastien Hergalant, Julia Vogt, et al.
Eclinicalmedicine|January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO groupAnne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Blood Cancer Discovery|December 5, 2022
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic VulnerabilitiesElisa Ten Hacken, Tomasz Sewastianik, Shanye Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular LymphomaFranck Morschhauser, Loretta Nastoupil, Pierre Feugier, et al.
Haematologica|February 22, 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphomaAnastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, et al.
Blood|March 31, 2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysisNicolas Gower, Pierre Feugier, Jason R Westin, et al.
The Lancet. Oncology|October 16, 2009
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trialNatacha Heutte, Henning H Flechtner, Nicolas Mounier, et al.
Pageof 17